| Literature DB >> 32157710 |
William J Turbitt1, Claire Buchta Rosean2, K Scott Weber3, Lyse A Norian1,4,5.
Abstract
Obesity is an established risk factor for many cancers and has recently been found to alter the efficacy of T cell-based immunotherapies. Currently, however, the effects of obesity on immunometabolism remain unclear. Understanding these associations is critical, given the fact that T cell metabolism is tightly linked to effector function. Thus, any obesity-associated changes in T cell bioenergetics are likely to drive functional changes at the cellular level, alter the metabolome and cytokine/chemokine milieu, and impact cancer immunotherapy outcomes. Here, we provide a brief overview of T cell metabolism in the presence and absence of solid tumor growth and summarize current literature regarding obesity-associated changes in T cell function and bioenergetics. We also discuss recent findings related to the impact of host obesity on cancer immunotherapy outcomes and present potential mechanisms by which T cell metabolism may influence therapeutic efficacy. Finally, we describe promising pharmaceutical therapies that are being investigated for their ability to improve CD8 T cell metabolism and enhance cancer immunotherapy outcomes in patients, regardless of their obesity status.Entities:
Keywords: T cell metabolism; immunotherapy; obesity; tumor immunology
Mesh:
Year: 2020 PMID: 32157710 PMCID: PMC7416819 DOI: 10.1111/imr.12849
Source DB: PubMed Journal: Immunol Rev ISSN: 0105-2896 Impact factor: 12.988